Rapport Therapeutics announced on October 27, 2026, that it had commenced a proposed $200 million public offering of common stock and a separate $150 million offering of convertible senior notes due in 2032. The Rapport stock offering would be accompanied by a proposed private placement with an investor.

Key Takeaways

  • The two public offerings can close independently, but the private placement depends on completion of the stock offering.
  • The notes’ interest rate and initial conversion rate will be determined when the notes offering is priced.
  • Rapport plans to use proceeds in part to fund clinical trials advancing its investigational drug RAP-219.

Rapport stock offering and private placement

Rapport, a clinical-stage biotechnology company, said it intends to enter into a share purchase agreement with an investor in a separately negotiated private placement. The investor would buy common shares at the same per-share price as in the public stock offering. The company did not disclose the size of the proposed private placement.

The company plans to give stock underwriters a 30-day option to buy up to an additional $30 million in shares. It also intends to give note underwriters a 30-day option to purchase up to an additional $22.5 million in principal amount of notes to cover any over-allotments.

The offerings remain subject to market and other conditions. Rapport said there is no assurance of their completion, timing, actual size or final terms.

Convertible note terms

The notes would be unsecured obligations, with interest payable semiannually in arrears. They would mature on December 1, 2032, unless converted, redeemed or repurchased earlier. Eligible holders could convert them during specified periods and in certain circumstances; Rapport could settle conversion in cash, shares or a combination of both.

Subject to limitations, Rapport could redeem notes for cash on or after December 6, 2030, if its share price meets a threshold of at least 130% of the applicable conversion price for a specified period. Certain corporate events could also give holders the right to require a cash repurchase, subject to conditions and limited exceptions.

Planned use of proceeds

Rapport intends to use net proceeds to fund ongoing and planned clinical trials advancing RAP-219, other research and development, working capital and general corporate purposes.

The company may also use some remaining proceeds for complementary businesses, technologies, products or assets, but said it has no agreements or commitments for such a transaction.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.